Advertisement

Topics

Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001

11:59 EST 21 Dec 2018 | Investing News Network

Gritstone Oncology (Nasdaq:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GRANITE-001 for the treatment of colorectal cancer. As quoted in the press release: GRANITE-001 is a personalized immunotherapy containing patient-specific … Continued

The post Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 appeared first on Investing News Network.

Original Article: Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001

NEXT ARTICLE

More From BioPortfolio on "Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...